Based on stakeholder feedback received in May 2015, CADTH has announced that in the limited instances where no Canadian patient group exists, individual patient and caregiver input will now be accepted for the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs, effective immediately.
Please note that for both CDR and pCODR, individual patient and caregiver input will not be accepted when one or more patient groups exist that represent the particular condition or tumour for which a drug under review is used. Where patient groups do exist, individual patients and caregivers are encouraged to work directly with a patient group to have their input included in the group’s submission.
Individual patients and caregivers who wish to submit input for a drug review should first contact CADTH at email@example.com or firstname.lastname@example.org to confirm the absence of a relevant patient group. Upon confirmation that no relevant patient group exists, CADTH will provide interested individuals with the individual patient and caregiver template for completion. The process for providing input, and how CADTH uses that input, remains the same as that for patient groups.
For more information about the individual patient input process for CDR, please visit the Patient Input section of the CADTH website.
For more information about the individual patient input process for pCODR, please visit the Patient Engagement Guide.